{"url_path":"/sec/nmra/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","accession_number":"0001193125-26-270328","cik":"0001885522","ticker":"NMRA","issuer_name":"Neumora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","primary_entity_key":"0001885522","primary_entity_name":"Neumora Therapeutics, Inc."},"word_count":697,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nPipeline and Business Update\n\nThe Company is focused on the following near-term anticipated potential milestones:\n\n \n\n \n•\n \n\nNMRA-511 (V1a receptor antagonist, Alzheimer’s disease agitation):\n\n \n\n \n•\n \n\nComplete multiple ascending dose cohort evaluating higher doses in healthy elderly volunteers in the fourth quarter of 2026.\n\n \n\n \n•\n \n\nData from this study will inform dose selection for a Phase 2b dose ranging study that the Company plans to initiate by the end of 2026.\n\n \n\n \n•\n \n\nNMRA-898 (M4 positive allosteric modulator, schizophrenia): report data from the ongoing Phase 1 study in the second half of 2026.\n\n \n\n \n•\n \n\nNMRA-215 (NLRP3 inhibitor, obesity):\n\n \n\n \n•\n \n\nComplete repeat 13-week rat toxicology study mid-2026 and provide a program update with its second quarter earnings release in August 2026.\n\n \n\n \n•\n \n\nInitiate clinical studies by year end 2026.\n\nFollowing the reduction in force described under Item 2.05 above, the Company expects its current cash and cash equivalents to provide runway into the third quarter of 2027.\n\nKOASTAL Summary Results\n\nThe KOASTAL-2 and -3 studies enrolled 430 and 422 adult patients with MDD, respectively. The primary endpoint of both KOASTAL-2 and -3 was change from baseline (“CFB”) to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS). In the KOASTAL-2 study patients treated with navacaprant 80 mg (n = 217) demonstrated a similar CFB to those treated with placebo (n = 213) [-12.2 vs -12.0; least-squares mean difference (“LSMD”) = -0.3; p = 0.813]. In the KOASTAL-3 study patients treated with navacaprant 80 mg (n = 212) demonstrated a numerically lower CFB than those treated with placebo (n = 210) [-10.1 vs -10.8; LSMD = 0.7; p = 0.480]. In patients enrolled after study optimizations, patients treated with navacaprant (n = 216) demonstrated a similar CFB to those treated with placebo (n = 210) [-12.1 vs -12.1; LSMD = 0.0; p = 0.976].\n\nNavacaprant was shown to be safe and generally well-tolerated with a safety profile consistent with prior studies.\n\nForward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements expressed or implied in this report include, but are not limited to, statements regarding the Company’s pipeline and anticipated milestones; the discontinuation of development of navacaprant; the reduction in force and expectations regarding annualized cost savings and restructuring charges; timing of the Company’s cash runway; and other statements that are not historical fact. These statements are based on Neumora’s current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: comparisons to efficacy results from other sponsors should be interpreted with caution due to differences in compounds, study designs, subject characteristics, and other factors that may limit direct comparability; the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in the Company’s clinical trials; risks related to its reliance on third parties, including CROs; risks related to serious or undesirable side effects of the Company’s therapeutic candidates; risks related to the Company’s ability to utilize and protect its intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations and other risks, including those described under the heading “Risk Factors” in Neumora’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the investor relations section of Neumora’s website at www.neumoratx.com and on the SEC’s website at www.sec.gov. Forward-looking statements contained in this report are made as of this date, and Neumora undertakes no duty to update such information except as required under applicable law."}